MEFV and COVID-19: The combined analysis of the presence of at least one of our two genetics biomarkers related to inflammasome activity (MEFV) and antiviral immunity (IFNAR2) was associated with an increase in COVID-19 severity risk with an OR  of 6.274 (95% CI) (2.430–16.201) (Table 3).